ESP1/SARC025 Global Collaboration: A Phase I Study of a Combination of the PARP Inhibitor, Niraparib and Temozolomide or Irinotecan in Patients With Previously Treated,Incurable Ewing Sarcoma

Trial Profile

ESP1/SARC025 Global Collaboration: A Phase I Study of a Combination of the PARP Inhibitor, Niraparib and Temozolomide or Irinotecan in Patients With Previously Treated,Incurable Ewing Sarcoma

Recruiting
Phase of Trial: Phase I

Latest Information Update: 23 Feb 2017

At a glance

  • Drugs Niraparib (Primary) ; Temozolomide (Primary) ; Irinotecan
  • Indications Ewing's sarcoma
  • Focus Adverse reactions
  • Most Recent Events

    • 10 May 2016 Irinotecan has been added to treatments, Niraparib will be studied in combination with irinotecan also, number of treatment arms increased from 1 to 2.
    • 04 May 2016 Planned number of patients changed from 30 to 50.
    • 04 May 2016 Planned primary completion date changed from 1 Feb 2016 to 1 Feb 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top